Both patients with inflammatory breast cancer (IFLBC) and patients with noninflammatory T4 breast cancer (non-IFLBC) have a heavy disease burden in the breast; whether the unique biology of IFLBC conveys a higher locoregional recurrence (LRR) risk and worse outcomes in comparison with other T4 lesions is uncertain. Here the outcomes of patients with IFLBC and patients with non-IFLBC treated with modern multimodality therapy are compared. METHODS: Patients with nonmetastatic T4 breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiation therapy between 2006 and 2016 were identified. Recurrences and survival were compared between patients with IFLBC and patients with non-IFLBC overall and stratified by receptor subtype. RESULTS: For 199 T4 patients, the median age was 52 years, and the median clinical tumor size was 7 cm. One hundred seventeen (59%) had IFLBC. With a median follow-up of 41 months, 4 patients had isolated LRR; all cases occurred in patients with IFLBC. The 5-year isolated LRR rate for patients with IFLBC was 4.8%. Overall, 14 patients had both LRR and distant recurrence (DR); 47 had DR only. The 5-year distant recurrence-free survival (DRFS) rates were similar for patients with IFLBC and patients with non-IFLBC (63% vs 71%; log-rank P = .14). The 5-year DRFS rate was lowest among triple-negative (TN) patients (43%) and was significantly lower for patients with TN IFLBC versus patients with non-IFLBC (28% vs 62%; log-rank P = .02). The 5-year overall survival rates (71% vs 74%; log-rank P = .4) and cancer-specific survival rates (74% vs 79%; log-rank P = .23) did not differ between IFLBC and non-IFLBC. CONCLUSIONS: Although IFLBC is often considered a unique biologic subtype, patients with IFLBC and patients with non-IFLBC had similar outcomes with modern multimodality therapy; isolated LRR was uncommon. The TN subtype in patients with IFLBC is associated with poor outcomes, and this indicates the need for new treatment approaches in this group. Cancer 2018;124:4314-4321.
INTRODUCTION
Inflammatory breast cancer (IFLBC) is rare and constitutes 1% to 5% of all breast cancers. [1] [2] [3] Both patients with IFLBC and patients with noninflammatory T4 breast cancer (non-IFLBC) have a heavy disease burden in the breast; however, IFLBC is characterized clinically by a rapid onset of symptoms, including skin edema and erythema encompassing at least one-third of the breast, and pathologically by the presence of tumor emboli in the dermal and parenchymal lymphatic vessels of the breast. 1, 4 Although the presence of tumor emboli in the dermal lymphatics is a hallmark of IFLBC, it is histologically identified in fewer than 75% of patients and is, therefore, not a requirement for diagnosis. 5 However, the mechanism of lymphatic obstruction resulting from lymphatic invasion is thought to contribute to the increased metastatic potential of IFLBC. 1 The prognosis of IFLBC is historically poor. In a cohort of patients with IFLBC treated with surgery and/or radiation from 1930 to 1970, the median overall survival (OS) was shorter than 15 months. 6 Outcomes improved with the addition of systemic therapy, and from 1973 to 1993, the median OS increased to 37 months with an estimated 5-year OS rate of 40%. 2 In a large population-based study of patients with IFLBC treated from 1990 to 2010, the 2-year breast cancer-specific survival (CSS) rate was 71%, and it improved over time. Increasing year of diagnosis was associated with a decreasing risk of death from breast cancer. 7 Recent literature suggests that in the age of modern multimodality therapy, outcomes for patients with IFLBC have improved dramatically, and the 5-year survival rate now approximates 69%. 8 Despite a similar burden of disease in the breast, patients with non-IFLBC have been reported to have more favorable outcomes than patients with IFLBC. Using Surveillance, Epidemiology, and End Results registry data between 2004
Cancer November 15, 2018 and 2007, Dawood et al 9 demonstrated superior 2-year breast CSS for patients with non-IFLBC versus patients with IFLBC (91% vs 84%; P < .0001). 9 However, this study was limited by its short median follow-up and a lack of information regarding the type of chemotherapy administered.
In the era of modern systemic treatment, it is unknown whether the unique biology of IFLBC conveys a worse prognosis than other T4 lesions treated in a similar manner. Furthermore, a comparison of outcomes for IFLBC and non-IFLBC based on the tumor subtype has not been examined. The purpose of this study was to perform a stage-matched comparison of outcomes and to examine the influence of the tumor subtype on prognosis for patients with stage IIIB and IIIC IFLBC and non-IF-LBC treated with modern multimodality therapy.
MATERIALS AND METHODS
After institutional review board approval, patients with nonmetastatic T4 breast cancer, which was defined as disease in the breast with skin or chest wall involvement, were identified from the institutional database at Memorial Sloan Kettering Cancer Center. A clinical diagnosis of IFLBC was made by the treating physician on the basis of the presence of diffuse edema, peau d'orange, and/or skin erythema. A skin biopsy demonstrating dermal lymphatic invasion was not required for diagnosis. Patients treated with neoadjuvant chemotherapy (NAC) followed by modified radical mastectomy (MRM) and postmastectomy radiation therapy (PMRT) between October 2006 and April 2016 were included. Patients with T4 breast cancer treated with breast-conserving surgery or limited axillary surgery with sentinel lymph node biopsy alone after NAC and those who did not receive NAC or PMRT were excluded from the study.
Clinicopathologic and treatment data were collected from each patient's medical record. Hormone receptor (HR) positivity was defined as more than 1% of cells staining positive for the estrogen or progesterone receptor, and the human epidermal growth factor receptor 2 (HER2) receptor was considered positive with immunohistochemical staining of 3+ or fluorescence in situ hybridization that was amplified. In this study, a pathologic complete response (pCR) to NAC was defined as no residual invasive disease in the breast or lymph nodes (in situ disease was allowed).
The NAC regimen administered was at the discretion of the treating medical oncologist, with most patients receiving doxorubicin and taxane-based chemotherapy. In addition to cytotoxic chemotherapy, all HER2-positive patients received targeted anti-HER2 therapy in the neoadjuvant setting. After NAC, all patients underwent MRM followed by PMRT to the chest wall, with 91% also receiving nodal radiation therapy. Overall, 79% of the patients received PMRT at Memorial Sloan Kettering Cancer Center with a standard dose of 50 Gy to the chest wall in patients with IFLBC and patients with non-IFLBC. A scar boost to 60 Gy was optional and at the discretion of the treating physician. All HR-positive patients were offered adjuvant endocrine therapy, and HER2-positive patients completed 1 year of anti-HER2 therapy.
Patient, disease, and treatment characteristics were summarized with medians and ranges for continuous variables, and with frequencies and percentages for categorical variables. Between-group comparisons were made with the Kruskal-Wallis test for continuous variables and with Fisher's exact test for categorical variables. Recurrences and survival were compared between patients with IFLBC and patients with non-IFLBC overall and stratified by receptor subtype and by the presence or absence of a pCR to NAC. Survival times were estimated from the date of surgery to the date of event or last follow-up. Patients without the event of interest were censored at the date of last follow-up. The KaplanMeier method was used to estimate survival probabilities. Between-group comparisons were made with the log-rank test. A P value less than .05 was considered statistically significant. All statistical analyses were conducted with R software (version 3.4.1; R Core Development Team, Vienna, Austria), including the survival package.
RESULTS
Of 199 patients with T4 breast cancer included in the study, 117 (59%) had IFLBC, and 82 (41%) had non-IFLBC. The median age was 52 years (range, 28-85 years), and the median clinical tumor size was 7 cm (range, 1.5-15 cm). The most common chemotherapy regimen was doxorubicin and cyclophosphamide followed by a taxane, which was received by 84% of the patients. The clinical characteristics of patients with IFLBC and patients with non-IFLBC are compared in Table 1 . Patients with IFLBC were more likely to be HER2-positive than patients with non-IFLBC (50% vs 28%; P = .02); the remaining characteristics, including the clinical nodal status at presentation, were similar.
Locoregional Recurrence (LRR)
At a median follow-up of 41 months, 4 patients had an isolated LRR, and all occurred in patients with IFLBC.
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The 5-year cumulative incidence of isolated LRR among patients with IFLBC was 4.8% (range, 0%-9.7%).
Overall, there were 18 locoregional events, including 14 patients who had a concurrent distant recurrence (DR). When we compared any local failure, the 5-year cumulative incidence of LRR was significantly higher for patients with IFLBC than patients with non-IFLBC (17% vs 4%; log-rank P = .005). LRR did not vary by tumor subtype (log-rank P = .28; Table 2 ), although this comparison was limited by the small number of local events.
DR
Sixty-one patients had a DR; 14 had both an LRR and a DR, and 47 had a DR only. The 5-year distant recurrence-free survival (DRFS) was similar for patients with IFLBC and patients with non-IFLBC (63% vs 71%; log-rank P = .14; Fig. 1A) . Among all T4 patients, the 5-year DRFS rate was lowest among triple-negative (TN) patients (43%) and highest among HR-positive/HER2-positive patients (79%; log-rank P < .001; Table 2 ). The 5-year DRFS rate was significantly lower for patients with TN IFLBC than patients with non-IFLBC (28% vs 62%; log-rank P = .02). Otherwise, DRFS did not differ significantly between IFLBC and non-IFLBC for other tumor subtypes (Fig. 1B) .
Survival OS (5-year OS, 71% vs 74%; log-rank P = .4) and CSS (5-year CSS, 74% vs 79%; log-rank P = .23) did not differ between patients with IFLBC and patients with non-IFLBC ( Fig. 2A) , although CSS did vary significantly by receptor subtype (log-rank P < .001), with patients with TN breast cancer having the lowest CSS (54%; Table 2 ). The 5-year CSS was lower for patients with TN IFLBC than patients with non-IFLBC (46% vs 62%), although Other includes doxorubicin and cyclophosphamide (n = 2), cisplatin (n = 1), doxorubicin and taxane (n = 1), and vinorelbine (n = 1). c Calculated for the HER2-positive patients (n = 82). d Other includes trastuzumab plus lapatinib (n = 5) and lapatinib alone (n = 1).
this did not reach statistical significance (log-rank P = .1). CSS did not differ significantly between patients with IFLBC and patients with non-IFLBC for the remaining tumor subtypes (Fig. 2B) .
Effect of pCR on Recurrence and Survival
The overall pCR rate was 26%, and it differed significantly by tumor subtype (HR positive/HER2 negative, 6%; HR positive/HER2 positive, 36%; HR negative/ HER2 positive, 61%; TN, 19%; P < .001) but not by T4 status (31% for IFLBC vs 20% for non-IFLBC; P = .1).
In patients achieving a pCR, there were no LRRs, and 5-year DRFS and CSS rates were higher than those for patients with residual disease after NAC (Table 3) .
DISCUSSION

IFLBC was first described in 1924 by Lee and
Tannenbaum, 10 and it has since been considered the most aggressive form of breast cancer with substantial rates of LRR and DR. As systemic and local therapy have improved over time, so have outcomes, [11] [12] [13] although further progress is still needed because the 5-year OS rate for T4 patients in our modern cohort was only 72%. Interestingly, T4 stage did not appear to influence the overall prognosis, with similar 5-year DRFS, CSS, and OS observed for patients with IFLBC and patients with non-IFLBC. As expected, the tumor biology and response to NAC were more important predictors of outcome than T4 stage alone.
Notably, locoregional failures, unlike distant failures, were more common in IFLBC. Isolated LRR among T4 patients treated with NAC, MRM, and PMRT was uncommon and occurred in only 4 patients, all with IFLBC. Although these low rates of locoregional failure are promising, they should not be taken as evidence that lesser breast surgery in patients with IFLBC is appropriate. Even with optimal systemic and surgical therapy, the 5-year cumulative incidence of any locoregional failure among patients with IFLBC was 17% when we included patients who had a concurrent distant failure; this was substantially higher than the 4% 5-year cumulative incidence seen among T4 patients with non-IFLBC. In this study, LRR did not vary by tumor subtype, although the small number of events limits interpretation of these findings. Although a local failure in the setting of a DR has no impact on prognosis, LRR can negatively affect quality of life, particularly when it is associated with ulceration or bleeding.
14 The high rate of local failure among patients with IFLBC seen in our study is comparable to that of prior reports 8, 15, 16 despite maximal therapy, and it supports the consensus statement by the International Expert Panel on Inflammatory Breast Cancer that after NAC, aggressive local therapy, including MRM and PMRT, remains the standard of care for patients with IFLBC. 1 In contrast, the low rate of local failure observed among T4 patients with non-IF-LBC is similar to that seen in patients with early-stage breast cancer treated with mastectomy 17 and supports trials examining surgical de-escalation or decreased use of radiotherapy in carefully selected patients with localized disease and an excellent response to NAC.
Prior studies have demonstrated higher rates of DR and worse disease-free survival with IFLBC versus non-IFLBC. In a retrospective analysis of 1071 patients from The University of Texas MD Anderson Cancer Center treated between 1974 and 2000, Cristofanilli et al 11 demonstrated worse 5-year relapse-free survival with IFLBC versus other locally advanced breast cancers (35% vs 56%; P < .001). However, the patients in the aforementioned study were treated in the pre-trastuzumab era, and outcomes were not compared according to tumor subtype because the receptor subtype was unknown for a significant number of cases. In our patient population, more than 80% of the patients received a doxorubicin and taxane-containing chemotherapy regimen, and all HER2-positive patients received HER2-targeted therapy, with 26% receiving dual therapy. With optimal systemic therapy, the DR rates, CSS, and OS were similar between patients with IFLBC and patients with non-IFLBC, but outcomes varied by biologic subtype, with HER2-positive cancers having the best 5-year CSS (82%-88%). This suggests that the tumor biology is a more important predictor of outcome than the inflammatory nature of breast cancer. Although the unique biology of IFLBC should not be ignored, the tumor subtype and response to treatment can be used to better stratify the prognosis for these patients. In the patients with locally advanced breast cancer in our cohort, the TN phenotype was associated with a Cancer November 15, 2018 substantial incidence of DR, with more than half of the patients (57%) developing metastatic disease by 5 years versus approximately one-quarter of HER2-positive patients. Patients with TN IFLBC had the worse prognosis, with a 5-year cumulative incidence of DR higher than 70% despite optimal systemic therapy, whereas it was less than 40% in the T4 patients with non-IFLBC. Similarly, in a modern cohort of patients with IFLBC from the Dana-Farber Cancer Institute treated predominantly with neoadjuvant anthracyclines and taxanes, the TN phenotype was associated with the shortest time to recurrence, even after adjustments for the pCR status, and this suggests that TN IFLBC may be potentially biologically distinct from TN non-IFLBC. 18 The significant disparity in outcomes between patients with TN IFLBC and patients with non-IFLBC in our study supports this hypothesis and highlights the need for ongoing research to better understand potential genetic differences between TN IFLBC and other TN cancers. Furthermore, the high rate of DR in T4 TN breast cancer patients overall, despite the receipt of optimal systemic therapy, suggests the need for new treatment approaches, particularly among those with IFLBC. Most of the patients in our study were treated before the adoption of extended adjuvant therapy with capecitabine for TN patients with residual disease after NAC; this practice was made standard at our institution after the publication of the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) trial. 19 Although extended adjuvant therapy will likely result in a modest improvement in survival for TN T4 patients, the development of novel targeted therapies for TN breast cancer is essential for improving outcomes; nevertheless, this remains an unmet goal.
Similarly to studies of patients with early-stage and locally advanced breast cancer, 18, 20 the prognosis was notably better among those patients achieving a pCR in comparison with those with residual disease after NAC, although the small number of events among those who achieved a pCR precluded statistical comparison. Although the observation in our study of no local failures among T4 patients who achieved a pCR is encouraging and raises hope for future surgical de-escalation, additional study is needed before we abandon aggressive surgical management, particularly among patients with IFLBC.
Our study is limited by its retrospective nature and small sample size because T4 cancers are uncommon, representing <5% of all breast cancers. 21 Our study population had a higher proportion of patients with IFLBC than patients with non-IFLBC, and this is inconsistent with other series of locally advanced breast cancer in which non-IFLBC is more common. 9, 11 This pattern likely reflects a referral bias, with fewer indolent T4 cancers referred to our institution for care. However, although the proportion of patients with IFLBC may not be generalizable to the larger population of T4 breast cancers, there is no reason to believe that this would affect the between-group comparisons. In addition, because of the small number of patients in our study, stage-matched comparisons by subtype may be underpowered to detect small differences in recurrence or survival. In particular, although anti-HER2 therapy was used for all patients with HER2-positive breast cancer, the small number of HER2-positive patients in the cohort (n = 82) may limit our ability to detect a difference in outcomes between IFLBC and non-IFLBC, despite a larger proportion of patients with HER2-positive cancer in the IFLBC subset (50% vs 28%; P = .02). Furthermore, our median follow-up remains short, particularly in the HR-positive cohort, and ongoing follow-up is needed to better understand long-term patterns of failure in patients with T4 breast cancer. Finally, 20% of the patients received PMRT at an outside institution; therefore, delivery of PMRT may not have been uniform, and this may have affected LRR rates. Despite these limitations, our cohort of T4 patients represents one of the largest in the literature treated with modern systemic therapy at a single institution in the trastuzumab era, and the initial results in this cohort are nonetheless meaningful.
In conclusion, although outcomes for patients with locally advanced T4 breast cancer have improved over time, 5-year DRFS and CSS remain suboptimal, with a 5-year CSS of only 76% despite aggressive multimodality treatment. Isolated LRR failures were uncommon, although the 5-year cumulative incidence of any LRR (with or without concurrent distant failure) was higher in patients with IFLBC and approached 20%; this supports continued aggressive surgical therapy in this group. Patients with IFLBC and non-IFLBC had similar outcomes overall when they were treated with modern systemic therapy; patients with TN IFLBC had a significantly lower DRFS rate than patients with TN non-IFLBC (5-year DRFS, 28% vs 62%), and this suggests that TN IFLBC may represent a distinct biologic
Cancer November 15, 2018 entity. Future research efforts should be focused on identifying unique genetic alterations in TN IFLBC that can be used to develop novel targeted therapies for treatment.
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